Latest Health News

REA Group has reported a robust FY25 with strong revenue and profit growth, underpinned by solid Australian market performance and strategic moves in India. The company also announced a leadership transition amid optimistic FY26 guidance.

Mayne Pharma has firmly rejected a fresh termination notice from Cosette Pharmaceuticals alleging breaches related to FDA disclosure, escalating an ongoing contractual dispute with significant legal implications.

Pinnacle Investment Management announces a fully franked dividend of AUD 0.27 per share for the half-year ending June 2025, offering shareholders a Dividend Reinvestment Plan with currency flexibility.

Nutritional Growth Solutions has completed a $760,000 share placement at a slight discount, aiming to boost inventory and support its retail growth strategy.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, exceeding guidance despite operational headwinds. However, EBITDA fell slightly short of forecasts, reflecting challenges in supply chains and market shifts.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

Credit Corp Group Limited has announced a fully franked ordinary dividend of AUD 0.36 per share for the six months ending June 2025, signaling steady returns for investors.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.